Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

FDA approves Onexton gel for the treatment of acne vulgaris

Nov. 26, 2014

Cosentyx receives positive CHMP opinion for first-line treatment of psoriasis

Nov. 24, 2014

Veltuzumab receives FDA orphan drug status for pemphigus

Nov. 21, 2014

FDA awards breakthrough therapy designation to dupilumab for atopic dermatitis

Nov. 20, 2014

Maruho announces results of the phase III study of M-8010 for the treatment of psoriasis vulgaris

Nov. 20, 2014

Quatsomes EGF formulation developed to treat diabetic foot ulcers

Nov. 14, 2014

Brodalumab superior to ustekinumab in phase III trial in moderate to severe plaque psoriasis

Nov. 12, 2014

Oral JAK1 inhibitor shows dose-dependent activity in phase II psoriasis trial

Nov. 10, 2014

LEO Pharma licenses Japan Tobacco's JTE-052 for dermatology applications

Nov. 7, 2014

Xoma opens enrollment in phase III study of gevokizumab for pyoderma gangrenosum

Nov. 7, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...